{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:58:31Z","timestamp":1793361511460,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy remains uncertain among high myopic children. This study aimed to evaluate the efficacy and safety of low-concentration atropine eye drop (0.01%) in high myopic children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A non-randomized, parallel-group, longitudinal interventional cohort study. Myopic children were divided into two groups: (1) the intervention arm of children who received one drop of topical 0.01% atropine once a day at bedtime and (2) the control arm, in which enrolled children who were on observation only. Repeated measurements of spherical equivalent refractive errors (SERs) were performed at baseline and 1 and 2 years after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 37 eyes were enrolled in the intervention arm (allocated to 0.01% atropine at year 1 follow-up) and 23 eyes in the control arm. After 1 year of 0.01% atropine therapy, the myopia progression was 0.15 \u00b1 0.9 D in the intervention group versus 1.1 \u00b1 1 D in the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Similarly, after 2 years of treatment, the myopia progression was 0.3 \u00b1 1.1 D in the intervention group versus 1.4 \u00b1 1.1 D in the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared to no treatment, 0.01% atropine treatment had shown better effect on myopia progression in high myopic children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_679_22","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:53:31Z","timestamp":1670316811000},"page":"4400-4404","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study)"],"prefix":"10.4103","volume":"70","author":[{"given":"Pradeep","family":"Agarwal","sequence":"first","affiliation":[{"name":"Departments of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashi","family":"Khurana","sequence":"additional","affiliation":[{"name":"Cornea and Anterior Segment, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veenu","family":"Maan","sequence":"additional","affiliation":[{"name":"Departments of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Sutar","sequence":"additional","affiliation":[{"name":"Optometry and Visual Sciences, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Clinical and Public Health Research, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","article-title":"Overview of the complications of high myopia","volume":"37","author":"Ikuno","year":"2017","journal-title":"Retina"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0970-0218.112436","article-title":"Is myopia a public health problem in India?","volume":"38","author":"Saxena","year":"2013","journal-title":"Indian J Community Med"},{"key":"R6-20251006","first-page":"602","article-title":"Epidemiology of myopia and prevention of myopia progression in children in East Asia:A review","volume":"24","author":"Mak","year":"2018","journal-title":"Hong Kong Med J"},{"key":"R7-20251006","first-page":"CD004916","article-title":"Interventions to slow progression of myopia in children","volume":"12","author":"Walline","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children:A network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study:A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2:Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4103\/ijo.IJO_418_17","article-title":"Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes","volume":"65","author":"Kothari","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia:Effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia:Changes after stopping atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_679_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:35Z","timestamp":1786647575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_679_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_679_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"2022-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}